{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T12:27:31Z","timestamp":1786883251117,"version":"build-2736575974"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["FOR5806"],"award-info":[{"award-number":["FOR5806"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.molmed.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T20:08:51Z","timestamp":1786565331000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of pharmacomicrobiomics in colorectal cancer therapy"],"prefix":"10.1016","author":[{"given":"Xiaoxi","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Pora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-3180","authenticated-orcid":false,"given":"Tianzuo","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2026.07.006_bb0005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","article-title":"Mapping human microbiome drug metabolism by gut bacteria and their genes","volume":"570","author":"Zimmermann","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.07.006_bb0010","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.gastro.2022.10.018","article-title":"Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy","volume":"164","author":"Chrysostomou","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2026.07.006_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1428420","article-title":"Pharmacomicrobiomics in precision cancer therapy: bench to bedside","volume":"15","author":"Le Ngoc","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0020","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-023-01619-w","article-title":"Drug-microbiota interactions: an emerging priority for precision medicine","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2026.07.006_bb0025","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41557-025-01789-w","article-title":"Activity of GPCR-targeted drugs influenced by human gut microbiota metabolism","volume":"17","author":"Wu","year":"2025","journal-title":"Nat. Chem."},{"key":"10.1016\/j.molmed.2026.07.006_bb0030","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.cell.2020.05.001","article-title":"Personalized mapping of drug metabolism by the human gut microbiome","volume":"181","author":"Javdan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.07.006_bb0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adq8870","article-title":"Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity","volume":"17","author":"Trepka","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2026.07.006_bb0040","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1021\/acschembio.9b00663","article-title":"Targeting regorafenib-induced toxicity through inhibition of gut microbial \u03b2-glucuronidases","volume":"14","author":"Ervin","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0045","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/s41564-022-01226-5","article-title":"Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism","volume":"7","author":"Spanogiannopoulos","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116473","article-title":"PreTA-mediated metabolism of 5-fluorouracil by intratumoral Citrobacter freundii drives chemoresistance in pancreatic cancer","volume":"44","author":"Xu","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2026.07.006_bb0055","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1126\/science.1191175","article-title":"Alleviating cancer drug toxicity by inhibiting a bacterial enzyme","volume":"330","author":"Wallace","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.07.006_bb0060","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.07.006_bb0065","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1124\/dmd.115.063545","article-title":"RNA-seq quantification of hepatic drug processing genes in germ-free mice","volume":"43","author":"Selwyn","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.molmed.2026.07.006_bb0070","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12866-020-01938-w","article-title":"A comprehensive analysis of the microbiota composition and gene expression in colorectal cancer","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0075","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/0008-5472.CAN-21-0453","article-title":"Fusobacterium nucleatum promotes the development of colorectal cancer by activating a cytochrome P450\/epoxyoctadecenoic acid axis via TLR4\/Keap1\/NRF2 signaling","volume":"81","author":"Kong","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.07.006_bb0080","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s42255-022-00558-0","article-title":"The gut microbial metabolite formate exacerbates colorectal cancer progression","volume":"4","author":"Ternes","year":"2022","journal-title":"Nat. Metab."},{"key":"10.1016\/j.molmed.2026.07.006_bb0085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41556-023-01314-6","article-title":"Gut microbial metabolite facilitates colorectal cancer development via ferroptosis inhibition","volume":"26","author":"Cui","year":"2024","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0090","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","article-title":"Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy","volume":"170","author":"Yu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.07.006_bb0095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.freeradbiomed.2024.04.226","article-title":"Fusobacterium nucleatum induces oxaliplatin resistance by inhibiting ferroptosis through E-cadherin\/\u03b2-catenin\/GPX4 axis in colorectal cancer","volume":"220","author":"Li","year":"2024","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.molmed.2026.07.006_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.634874","article-title":"Butyrate suppresses glucose metabolism of colorectal cancer cells via GPR109a-AKT signaling pathway and enhances chemotherapy","volume":"8","author":"Geng","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.molmed.2026.07.006_bb0105","doi-asserted-by":"crossref","first-page":"13063","DOI":"10.1038\/s41598-024-63993-x","article-title":"Microbial metabolite sodium butyrate enhances the anti-tumor efficacy of 5-fluorouracil against colorectal cancer by modulating PINK1\/Parkin signaling and intestinal flora","volume":"14","author":"Li","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2026.07.006_bb0110","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jcmgh.2021.06.001","article-title":"Lactobacillus rhamnosus GG orchestrates an antitumor immune response","volume":"12","author":"Owens","year":"2021","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0115","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/gutjnl-2020-323426","article-title":"Lactobacillus rhamnosus GG induces cGAS\/STING-dependent type I interferon and improves response to immune checkpoint blockade","volume":"71","author":"Si","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2026.07.006_bb0120","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41591-020-0882-8","article-title":"Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer","volume":"26","author":"Roberti","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2026.07.006_bb0125","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s41416-025-03105-2","article-title":"Impact of gut microbiome on radiotherapy and immunotherapy efficacy in microsatellite-stable colorectal cancer: role of propionic acid and B. fragilis","volume":"133","author":"Yu","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molmed.2026.07.006_bb0130","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.immuni.2024.02.014","article-title":"Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8+ T cell effector functions","volume":"57","author":"Cong","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2026.07.006_bb0135","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320904293","article-title":"Composition of fecal microbiota in low-set rectal cancer patients treated with FOLFOX","volume":"11","author":"Li","year":"2020","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"10.1016\/j.molmed.2026.07.006_bb0140","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1007\/s10238-023-01048-7","article-title":"Fecal levels of SCFA and BCFA during capecitabine in patients with metastatic or unresectable colorectal cancer","volume":"23","author":"Ziemons","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.molmed.2026.07.006_bb0145","first-page":"e87","article-title":"The role of intestinal microbiota in metastatic colorectal cancer patients treated with capecitabine","volume":"21","author":"Aarnoutse","year":"2022","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.molmed.2026.07.006_bb0150","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s12602-025-10595-2","article-title":"Screening of fecal Bacteroides strains and discovery of Bacteroides eggerthii S13-F8 with protective effects against chemotherapy-induced diarrhea","volume":"18","author":"Zhao","year":"2026","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"10.1016\/j.molmed.2026.07.006_bb0155","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.07.006_bb0160","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cmet.2021.03.002","article-title":"Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity","volume":"33","author":"He","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2026.07.006_bb0165","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12866-023-02791-3","article-title":"Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity","volume":"23","author":"Mahdy","year":"2023","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0170","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/gutjnl-2024-334699","article-title":"Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites","volume":"75","author":"Hou","year":"2026","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2026.07.006_bb0175","article-title":"\u03b2-Glucuronidase-expressing Lactobacillus reuteri triggers irinotecan enterotoxicity through depleting the regenerative epithelial stem\/progenitor pool","volume":"12","author":"Yue","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.molmed.2026.07.006_bb0180","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13046-018-0985-y","article-title":"Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer","volume":"38","author":"Zhang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2026.07.006_bb0185","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2295384","article-title":"Fusobacterium nucleatum promotes inflammatory and anti-apoptotic responses in colorectal cancer cells via ADP-heptose release and ALPK1\/TIFA axis activation","volume":"16","author":"Martin-Gallausiaux","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.molmed.2026.07.006_bb0190","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2186114","article-title":"Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer","volume":"15","author":"Xu","year":"2023","journal-title":"Gut Microbes"},{"key":"10.1016\/j.molmed.2026.07.006_bb0195","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.chom.2025.05.004","article-title":"Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity","volume":"33","author":"Ding","year":"2025","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.molmed.2026.07.006_bb0200","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12916-025-04233-5","article-title":"Mitigation of chemotherapy-induced gut dysbiosis and diarrhea by supplementation with heat-killed Bacteroides fragilis","volume":"23","author":"Yan","year":"2025","journal-title":"BMC Med."},{"key":"10.1016\/j.molmed.2026.07.006_bb0205","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1007\/s12602-024-10324-1","article-title":"Pediococcus pentosaceus PP34 ameliorates 5-fluorouracil-induced intestinal mucositis via inhibiting oxidative stress and restoring the gut microbiota","volume":"17","author":"He","year":"2025","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"10.1016\/j.molmed.2026.07.006_bb0210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12866-023-03152-w","article-title":"Bifidobacterium longum SX-1326 ameliorates gastrointestinal toxicity after irinotecan chemotherapy via modulating the P53 signaling pathway and brain-gut axis","volume":"24","author":"Yue","year":"2024","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0215","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41538-025-00473-0","article-title":"Improved gut microbiota by selenium-enriched Bifidobacterium longum DD98 alleviates chemotherapy-induced intestinal mucositis via inhibiting the STING pathway","volume":"9","author":"Qiu","year":"2025","journal-title":"npj Sci. Food"},{"key":"10.1016\/j.molmed.2026.07.006_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105041","article-title":"Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3","volume":"102","author":"Li","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.molmed.2026.07.006_bb0225","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.7150\/thno.70754","article-title":"Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis","volume":"12","author":"Ghosh","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.molmed.2026.07.006_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107636","article-title":"Gut microbiota derived DCA enhances FOLFOX efficacy via Ugt1a6b mediated enterohepatic circulation in colon cancer","volume":"213","author":"Fang","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.molmed.2026.07.006_bb0235","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12967-023-04036-3","article-title":"Lactobacillusrhamnosus GG cell-free supernatant as a novel anti-cancer adjuvant","volume":"21","author":"Salemi","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.molmed.2026.07.006_bb0240","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12275-022-1533-1","article-title":"Lactobacillus plantarum-derived metabolites sensitize the tumor-suppressive effects of butyrate by regulating the functional expression of SMCT1 in 5-FU-resistant colorectal cancer cells","volume":"60","author":"Kim","year":"2022","journal-title":"J. Microbiol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0245","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbrc.2022.04.135","article-title":"Akkermansia muciniphila and its outer membrane protein Amuc_1100 prophylactically attenuate 5-fluorouracil-induced intestinal mucositis","volume":"614","author":"Chen","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2026.07.006_bb0250","doi-asserted-by":"crossref","first-page":"61","DOI":"10.38212\/2224-6614.3535","article-title":"Bacillus coagulans 198 and L-glutamine in combination attenuated intestinal mucositis in a 5-FU-induced BALB\/c mouse model via modulation of gut microbial community structure and diversity","volume":"33","author":"Chen","year":"2025","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.molmed.2026.07.006_bb0255","article-title":"Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis","volume":"2","author":"Wang","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.molmed.2026.07.006_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102315","article-title":"Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)","volume":"66","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.molmed.2026.07.006_bb0265","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.62347\/XKUJ3012","article-title":"Updated outcomes and exploratory analysis of RENMIN-215: tislelizumab plus fruquintinib and fecal microbiota transplantation in refractory microsatellite stable metastatic colorectal cancer","volume":"14","author":"Zhao","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.molmed.2026.07.006_bb0270","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"10.1016\/j.molmed.2026.07.006_bb0275","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41392-021-00795-x","article-title":"Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer","volume":"6","author":"Gao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2026.07.006_bb0280","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.ccell.2024.08.019","article-title":"Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2026.07.006_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1586146","article-title":"Fusobacterium nucleatum downregulated MLH1 expression in colorectal cancer by activating autophagy-lysosome pathway","volume":"16","author":"Ding","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0290","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2442037","article-title":"Fusobacterium nucleatum-driven CX3CR1+ PD-L1+ phagocytes route to tumor tissues and reshape tumor microenvironment","volume":"17","author":"Chen","year":"2025","journal-title":"Gut Microbes"},{"key":"10.1016\/j.molmed.2026.07.006_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2025.111495","article-title":"Fusobacterium nucleatum-derived 3-indolepropionic acid promotes colorectal cancer progression via aryl hydrocarbon receptor activation in macrophages","volume":"414","author":"Song","year":"2025","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.molmed.2026.07.006_bb0300","doi-asserted-by":"crossref","DOI":"10.1111\/apm.70134","article-title":"Fusobacterium nucleatum enhances immune escape in colorectal cancer by inducing H3K18 lactylation of CD274 (PD-L1) protein through lactate accumulation","volume":"134","author":"Li","year":"2026","journal-title":"APMIS"},{"key":"10.1016\/j.molmed.2026.07.006_bb0305","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1158\/1078-0432.CCR-20-4009","article-title":"Association of Fusobacterium nucleatum with specific T-cell subsets in the colorectal carcinoma microenvironment","volume":"27","author":"Borowsky","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2026.07.006_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1453","article-title":"Inverse relationship between Fusobacterium nucleatum amount and tumor CD274 (PD-L1) expression in colorectal carcinoma","volume":"12","author":"Ugai","year":"2023","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0315","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.cell.2024.02.022","article-title":"Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer","volume":"187","author":"Jia","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.07.006_bb0320","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1136\/gutjnl-2023-329543","article-title":"Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1\/Kyn\/AHR axis","volume":"72","author":"Fong","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2026.07.006_bb0325","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.cmet.2023.04.015","article-title":"Lactobacillus plantarum-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8+ T cell immunity","volume":"35","author":"Zhang","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2026.07.006_bb0330","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1039\/D3FO02018E","article-title":"Dietary Lactobacillus rhamnosus GG extracellular vesicles enhance antiprogrammed cell death 1 (anti-PD-1) immunotherapy efficacy against colorectal cancer","volume":"14","author":"Lu","year":"2023","journal-title":"Food Funct."},{"key":"10.1016\/j.molmed.2026.07.006_bb0335","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1136\/gutjnl-2022-327853","article-title":"Acetyltransferase from Akkermansia muciniphila blunts colorectal tumourigenesis by reprogramming tumour microenvironment","volume":"72","author":"Jiang","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2026.07.006_bb0340","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1136\/gutjnl-2019-320105","article-title":"A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8+ T cells in mice","volume":"69","author":"Wang","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2026.07.006_bb0345","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202403295RR","article-title":"Amuc_1434 from Akkermansia muciniphila enhances CD8+ T cell-mediated anti-tumor immunity by suppressing PD-L1 in colorectal cancer","volume":"39","author":"Zhu","year":"2025","journal-title":"FASEB J."},{"key":"10.1016\/j.molmed.2026.07.006_bb0350","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gutjnl-2024-333020","article-title":"Fasting-mimicking diet-enriched Bifidobacterium pseudolongum suppresses colorectal cancer by inducing memory CD8+ T cells","volume":"74","author":"Nan","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2026.07.006_bb0355","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1136\/gutjnl-2023-330291","article-title":"Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells","volume":"72","author":"Kang","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2026.07.006_bb0360","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1002\/ijc.32920","article-title":"Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer","volume":"146","author":"Lop\u00e8s","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.molmed.2026.07.006_bb0365","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41572-023-00432-7","article-title":"Young-onset colorectal cancer","volume":"9","author":"Spaander","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.molmed.2026.07.006_bb0370","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.biopha.2018.08.165","article-title":"The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer","volume":"108","author":"Yuan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.molmed.2026.07.006_bb0375","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3389\/fmicb.2020.00814","article-title":"Gut microbiome influences the efficacy of PD-1 antibody immunotherapy on MSS-type colorectal cancer via metabolic pathway","volume":"11","author":"Xu","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0380","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","article-title":"Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer","volume":"31","author":"Jiang","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.molmed.2026.07.006_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202306281","article-title":"Antibacterial Fusobacterium nucleatum-mimicking nanomedicine to selectively eliminate tumor-colonized bacteria and enhance immunotherapy against colorectal cancer","volume":"35","author":"Chen","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.molmed.2026.07.006_bb0390","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/s41587-023-01957-8","article-title":"Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses","volume":"42","author":"Wang","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0395","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/nu15020356","article-title":"Postoperative probiotics administration attenuates gastrointestinal complications and gut microbiota dysbiosis caused by chemotherapy in colorectal cancer patients","volume":"15","author":"Huang","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.molmed.2026.07.006_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1168654","article-title":"Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12\u00ae Lactobacillus rhamnosus LGG\u00ae in colorectal cancer patients","volume":"13","author":"Mego","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0405","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41467-024-44776-4","article-title":"Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia","volume":"15","author":"Gurbatri","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.07.006_bb0410","doi-asserted-by":"crossref","DOI":"10.1155\/ijcp\/8052716","article-title":"Assessing the safety and efficacy of fecal microbiota transplantation for severe chemotherapy-induced diarrhea in colorectal cancer patients: a single-arm clinical trial","volume":"2025","author":"Alnaggar","year":"2025","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.molmed.2026.07.006_bb0415","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013823","article-title":"Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study","volume":"14","author":"Zhang","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2026.07.006_bb0420","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12866-024-03384-4","article-title":"Prebiotic fibre mixtures counteract the manifestation of gut microbial dysbiosis induced by the chemotherapeutic 5-Fluorouracil (5-FU) in a validated in vitro model of the colon","volume":"24","author":"Ziemons","year":"2024","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0425","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/jgh.14890","article-title":"Modulations of probiotics on gut microbiota in a 5-fluorouracil-induced mouse model of mucositis","volume":"35","author":"Yeung","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0430","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202403587","article-title":"5-Fluorouracil loaded prebiotic-probiotic liposomes modulating gut microbiota for improving colorectal cancer chemotherapy","volume":"14","author":"Sun","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.molmed.2026.07.006_bb0435","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1038\/s41467-023-40439-y","article-title":"Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy","volume":"14","author":"Lang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.07.006_bb0440","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2380061","article-title":"MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody","volume":"16","author":"Lee","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.molmed.2026.07.006_bb0445","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00689-25","article-title":"Synergistic effects of Clostridium butyricum and Akkermansia muciniphila-derived postbiotics ameliorate DSS-induced colitis and associated tumorigenesis through immunomodulation and microbiota regulation in mice","volume":"11","author":"Hua","year":"2026","journal-title":"mSystems"},{"key":"10.1016\/j.molmed.2026.07.006_bb0450","doi-asserted-by":"crossref","DOI":"10.12998\/wjcc.v13.i27.107704","article-title":"Enterococcal autoprobiotics in the complex treatment of colorectal cancer patient receiving chemotherapy: two case reports and review of literature","volume":"13","author":"Ermolenko","year":"2025","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.molmed.2026.07.006_bb0455","doi-asserted-by":"crossref","DOI":"10.1111\/1751-7915.70241","article-title":"Precision antimicrobial therapy against Fusobacterium nucleatum using bioengineered probiotics expressing guided antimicrobial peptides (gAMPs)","volume":"18","author":"Choudhury","year":"2025","journal-title":"Microb. Biotechnol."},{"key":"10.1016\/j.molmed.2026.07.006_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114291","article-title":"Engineered tumor-symbiotic bacterial membrane nanovesicles enable precise immuno-chemotherapy of colorectal cancer","volume":"388","author":"Lu","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2026.07.006_bb0465","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/ijms21020386","article-title":"Fecal microbiota transplantation prevents intestinal injury, upregulation of toll-like receptors, and 5-fluorouracil\/oxaliplatin-induced toxicity in colorectal cancer","volume":"21","author":"Chang","year":"2020","journal-title":"Int. J. Mol. Sci."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491426001760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491426001760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T11:25:03Z","timestamp":1786879503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491426001760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":93,"alternative-id":["S1471491426001760"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2026.07.006","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of pharmacomicrobiomics in colorectal cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}